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Regioselective and enantiospeciﬁc synthesis of the
HSP co-inducer arimoclomol from chiral glycidyl
derivatives†
Benjamin N. Atkinson, Hannah L. Woodward, James Sipthorp and
Paul V. Fish *
A new eﬃcient chiral synthesis of enantiopure arimoclomol (2) is
reported from (R)-(−)-glycidyl nosylate (11) with complete retention
of chiral integrity. Oﬀ-target pharmacology of arimoclomol (2) was
evaluated against a representative set of drug targets and showed
modest binding to a few kinases. Pharmacokinetic data was gener-
ated in vivo in mouse and showed a low brain : plasma ratio. These
studies will be helpful towards a better understanding of the
PK-PD relationship of 2 in disease models.
Introduction
Defects in proteostasis are a common feature of various neuro-
degenerative diseases.1,2 Cells have a dedicated protein folding
and quality control apparatus to protect against misfolding
and aggregation of proteins, including the heat shock response
(HSR) and the unfolded protein response (UPR). In the HSR,
cell stress leads to the dissociation of heat shock proteins 90
(HSP90) and 70 (HSP70) from heat shock factor 1 (HSF1),
allowing the HSPs to subsequently bind to misfolded proteins.
Unbound monomeric transcription factor HSF1 forms trimers
and translocates from the cytosol to the nucleus where it binds
to heat shock elements on DNA, inducing transcription of
HSPs.3 The HSR stabilises and refolds misfolded proteins, pre-
venting aggregation and subsequent cellular toxicity in several
models of protein aggregation induced cell death.4
The small molecules bimoclomol (1) and arimoclomol (2)
(Fig. 1) have been reported to be HSP co-inducers.5–9 When
added to cells in the absence of cell stress, 1 and 2 do not
elicit a chaperone response. In contrast, in the presence of cell
stress (e.g. heat shock, HSP90 inhibition or protein aggregates),
1 and 2 potentiate the induction of HSPs and help protect
cells from damage. This apparent activity-dependence makes
them an attractive means of modulating this ubiquitous cellu-
lar pathway for potential therapeutic benefit.
Arimoclomol (2) has progressed to human clinical studies for
evaluation as a potential treatment for SOD1 positive familial
amyotrophic lateral sclerosis (ALS) (NCT00706147).10 This study
was a phase II randomized, double-blind, placebo-controlled trial
that included 36 patients with rapidly progressive ALS due to
mutations in the SOD1 gene. Patients were treated with 2 at a dose
of 200 mg three times per day for up to 12 months. The primary
outcome was safety and tolerability; secondary outcome was
eﬃcacy as measured in terms of survival and functional decline.11
There has also been multiple reports demonstrating the eﬃcacy of
1 and 2 in in vitro and in vivo preclinical models of neurodegenera-
tion,5 retinal degeneration,6 sphingolipidoses,7 inclusion body
myositis8 and other conditions.9 However, the molecular target(s)
of 1 and 2 in these models has not yet been determined.
Herein, we disclose a new regioselective and enantiospecific syn-
thesis of the HSP co-inducers 1 and 2 from chiral glycidyl deriva-
tives. This new method is suitable for the synthesis of analogues to
establish structure–activity-relationships (SAR) required to direct
the creation of chemical probe reagents suitable for target pulldown
experiments in relevant cellular models of disease. In addition, we
report pharmacology and pharmacokinetic studies which will be
helpful in gaining a better understanding of the pharmacokinetic-
pharmacodynamic (PK-PD) relationship of 2 in disease models.
Results and discussion
Chemistry
Our first synthesis of 2 was undertaken by reproduction of the
published patent route (Scheme 1).12 Addition of NH2OH·HCl
Fig. 1 Structures of (±)-bimoclomol (1) and (R)-(+)-arimoclomol (2).
†Electronic supplementary information (ESI) available: Experimental procedures
and data for all new compounds including traces of chiral SFC. See DOI:
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to 3-cyanopyridine-N-oxide (3) gave the amidoxime 4 which
was then coupled with 2-hydroxy-4-azoniaspiro[3.5]nonane
chloride (6) (derived from (±)-epichlorohydrin (5) and piper-
idine) to yield the O-alkylated amidoxime 7. Diazotisation of 7
followed by in situ chlorination with HCl gave racemic arimo-
clomol (8) in moderate yield over the 2 steps. Initially, resolu-
tion of (±)-8 using (−)-dibenzoyl-L-tartaric acid, followed by
conversion to the preferred citrate salt, furnished 2 as the
desired (R)-enantiomer with modest eﬃciency.12 Separation of
(±)-8 by preparative supercritical fluid chromatography (SFC)
gave (R)-(+)-arimoclomol (2) (er, R : S, 98 : 2) and (S)-(−)-arimo-
clomol (9) (er, R : S, 1 : >99). The enantiomers were assigned
based on comparison with an authentic sample of (R)-(+)-ari-
moclomol citrate (er, R : S, 99 : 1).13
However, this linear synthetic approach, and necessity for pre-
parative SFC to produce enantiopure compounds, would not allow
for the direct preparation of homochiral analogues.14 Hence, our
aim was to develop a robust, eﬃcient and enantioselective route to
novel analogues of 1 and 2, which, combined with simple late
stage modifications, would allow facile exploration of the SAR.
Retrosynthetic analysis of 2 shows a disconnection into a
central chiral glycidyl synthon which could be sequentially
functionalised to introduce the aldoxime and amine com-
ponents (Scheme 2). The stereochemical integrity at C2 would
be retained by sequential and specific reaction at C1 followed
by C3 of the glycidyl synthon (Scheme 2). Two complementary
methods would support the development of SAR at the right-
hand side (RHS) amine (path a) and left-hand side (LHS) pyri-
dine (path b) groups from advanced intermediates by the
double application of a suitable glycidyl synthon.
Our initial experiments with (R)-(−)-epichlorohydrin (10)
(ee > 97.5%)15 as a glycidyl synthon were flawed as reactions
with amidoxime 4 gave poor yields of desired products and
were accompanied by lack of discrimination between C1 and
C3. In contrast, the use of (R)-(−)-glycidyl nosylate (11) (ee >
97.5%)15 was specific for the C1 reaction with the sodium alk-
oxide of 4 as the first nucleophile to yield epoxide intermediate
13, followed by C3 reaction with piperidine as the second
nucleophile, to aﬀord 12 in 71% yield (Scheme 3) (Scheme 2,
path a). The regiospecific and sequential reactions of 11 with
alkoxide and then amine nucleophiles is in accord with the
precedent of Sharpless who developed this methodology
with phenols and applied it to the preparation of β-blocker
(2S)-(−)-penbutolol.16 The reaction was operationally simple and
was performed as a one-pot procedure by the three-step sequen-
tial addition of NaH, 11 and then piperidine to 4 in DMF. This
reaction is highly atom-eﬃcient as 20/21 heavy atoms of 2 are
installed from readily available starting materials.
As before, diazotisation of 12 followed by in situ chlori-
nation with HCl gave (R)-(2) with subsequent salt formation
giving (R)-(2) citrate (Scheme 3).17 The absolute configuration
of 2 was confirmed as the (R)-enantiomer by chiral SFC with
an enantiomeric ratio (R : S) of >99 : 1 showing retention of
chiral integrity of C2 throughout.13
This short sequence was also performed employing (Z)-pyri-
dine-3-amidoxime as the amidoxime starting material giving
(R)-bimoclomol (1) maleate18 with a high enantiopurity (er, R : S,
99 : 1).13 Furthermore, it is important to note that the epoxide inter-
mediate 13 could be intercepted by a number of amines to give a
variety of amino analogues of 2 for the development of SAR.19
(R)-(−)-Glycidyl nosylate 11 was also conveniently used as
the starting material to develop an advanced intermediate 16
for the exploration of the SAR of the pyridinyl chloro-oxime
Scheme 1 Synthesis of arimoclomol (2) by reproduction of the published patent route. Reagents and conditions: (a) NH2OH·HCl (1.2 equiv.),
NaHCO3 (1.2 equiv.), H2O, rt, 18 h 91%; (b) piperidine (0.9 equiv.), MeOH, 65 °C, quant.; (c) 6, NaOH (1.3 equiv.), EtOH, H2O, 70 °C, 18 h; (d) NaNO2
(1.3 equiv.), conc. HCl, H2O, −5 °C, 2.5 h 51% over 2 steps; (e) (−)-dibenzoyl-L-tartaric acid, EtOH then NaOH, CH2Cl2; (f ) citric acid (1.0 equiv.),
acetone; (g) supercritical ﬂuid chromatography.
Scheme 2 Retrosynthetic analysis of 2 towards a central chiral glycidyl
synthon.
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moiety of 2 (Scheme 4) (Scheme 2, path b). Benzophenone
oxime, an N-protected hydroxylamine synthon, underwent
reaction at C1 of 11 to give epoxide 14 in a good yield.
Regioselective ring opening of epoxide 14 with piperidine gave
15 and subsequent acid hydrolysis of the benzophenone
protecting group unmasked the required O-alkylated hydroxyl-
amine 16 which was isolated as the mono HCl salt after treat-
ment with the weakly basic polymeric resin Amberlyst A21.
The next step in the sequence initially proved problematic.
The addition of hydroxylamine 16 into 3-cyanopyridine-N-
oxide (3) was sluggish (<10% conversion) and heating at elev-
ated temperatures caused a nitrile hydration product to form.
However, the application of thioglycolic acid (17) as a nucleo-
philic promoter gave amidoxime 12 in good yield.20,21
Performing the reaction under identical conditions but
without 17 gave <5% conversion to 12 showing the critical
importance of 17 in promoting this reaction. Conversion of 12
into 2 was again achieved by standard conditions (er, R : S,
>99 : 1).13 The analogous sequence was also performed with
3-cyanopyridine giving (R)-(+)-bimoclomol 1 with a high enan-
tiomeric ratio (er, R : S, >99 : 1).13 The addition of hydroxyl-
amine 16 to pyridine nitriles promoted by 17 proved to be suc-
cessful with a number of substrates and gave access to functio-
nalised pyridine analogues of 2.19
With (R)-(+)-bimoclomol 1 in hand, synthesis of (R)-(+)-ari-
moclomol 2 was completed by development of a selective
method for pyridine N-oxidation of (R)-1 to 2 (Scheme 5). This
method was of significant value as it would deliver a short syn-
thesis of both 1 and 2 from common chiral intermediates.
This conversion has been reported by oxidation of 1 mesylate
with H2O2 in AcOH to yield 2 on multigram scale.
22 When this
method was repeated, albeit on smaller scale, the reaction was
found to be capricious and product yields varied greatly.
Scheme 4 Chiral hydroxylamine route to arimoclomol (2). Reagents
and conditions: (a) (i) NaH (60% wt), DMF, 0 °C, 0.5 h; (ii) (R)-(−)-glycidyl
nosylate (11) (1.1 equiv.), rt, 2 h, 83%; (b) piperidine (1.05 equiv.), iPrOH,
50 °C, 18 h, quant.; (c) HCl (6 M), 95 °C, 18 h; quant.; (d) Amberlyst A21,
MeOH, rt, 4 h, 98%; (e) 3-cyanopyridine-N-oxide (3) (0.8 equiv.),
HSCH2CO2H (17) (1.5 equiv.), Et3N, EtOH, 85 °C, 24 h, 75%; (f ) NaNO2
(1.3 equiv.), conc. HCl, H2O, −5 °C, 66%.
Scheme 3 Arimoclomol (2) synthesis via chiral glycidyl nosylate synthon. Reagents and conditions: (a) (i) NaH (60% wt), DMF, 0 °C, 0.5 h; (ii) (R)-(−)-
glycidyl nosylate (11) (1.06 equiv.), rt, 2 h; (iii) piperidine (1.1 equiv.), 80 °C for 4 h then rt for 18 h, 71%; (b) NaNO2 (1.3 equiv.), conc. HCl, H2O, −5 °C,
2.5 h, 73%.
Scheme 5 Oxidation of bimoclomol (1) to arimoclomol (2) and other N-oxide derivatives. Reagents and conditions: (a) MeSO3H (1.0 equiv.), AcOH, then
30% H2O2 (4.0 equiv.), 60 °C, 24 h, 2 isolated in 31%; (b) (i) PhSO3H (1.3 equiv.), acetone, rt, 1.5 h; (ii) H2NC(O)NH2·H2O2, (2.0 equiv.), (CF3CO)2O (2.0
equiv.), MeCN, −5 °C→ rt, 18 h, 2 isolated in 55–60%.
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Although the high er was maintained, the maximum yield
achieved in producing 2 from (R)-1 and was 31%.
We began exploring a number of procedures for the selec-
tive N-oxidation of a pyridine in the presence of a sec-alcohol
and/or tert-amine. Initially we used mCPBA in the presence of
MsOH, the rationale being that the organic acid weakens the
nucleophilicity of the tert-amine, preventing oxidation.
However only the piperidine N-oxide 18 was produced in 31%
yield under these conditions. Subsequently, it was found that
pre-forming the mono-besylate salt of (R)-1 followed by oxi-
dation with urea-hydrogen peroxide adduct with trifluoroacetic
anhydride in MeCN gave a selectivity for 2 over 18.23,24
Pyridine N-oxide 2 was isolated from the reaction mixture in
typically 55–60% yield. The high er from (R)-1 (er, R : S, 98 : 2)
was retained in 2 (er, R : S, 98 : 2) after the oxidation.13
General pharmacology of arimoclomol
The use of target-aligned small molecule tools in cell-based
screens requires an investigation of their associated pharma-
cology to understand the selectivity window over any oﬀ-target
activities. For phenotypic screening of small molecule hits,
where the primary target(s) has not been identified, general
pharmacology screening is important to establish the degree
of likely selectivity (or promiscuity) against a set of representa-
tive traditional drug targets.
Arimoclomol (2) was screened for oﬀ-target pharmacology
against a panel of 50 representative classical receptors, trans-
porters and ion channels, and a panel of 50 representative
kinases, and was found to have modest binding aﬃnity for the
FGR kinases along with a few other weaker aﬃnities
(Table 1).25 Hence, we recommend screening of 2 in cellular
assays should be restricted to concentrations below 10 μM to
avoid acting through promiscuous undefined polypharma-
cology which could confound the interpretation of biological
results.
Pharmacokinetics of arimoclomol
Pharmacokinetic data for arimoclomol (2) was generated
in vivo in mouse (Table 2). The route of administration and
dose were selected to most closely match a number of relevant
published mouse disease model studies.5,26 Following single
intraperitoneal (i.p.) injection of 10 mg kg−1, plasma clearance
was high relative to liver blood flow resulting in a plasma
elimination half-life of 0.71 hours.
Compound 2 has a low brain : plasma ratio in mouse of just
16% based on AUCinf, however, these studies are somewhat
confounded by the high clearance of 2 which means steady
state is unlikely to have been achieved with single acute
dosing. The plasma half-life and brain penetration values from
these mouse PK experiments are consistent with published
preclinical PK data in rat and dog where a relatively short half-
life was observed in both species (T1/2 1 and 2 h respectively).
27
These data will contribute to the understanding of drug levels
of 2 to overlay with appropriate in vivo eﬃcacy endpoints, i.e.
the PK-PD relationship.
Conclusions
A new eﬃcient chiral synthesis of enantiopure 1 and 2 is
reported from (R)-(−)-glycidyl nosylate (11) with retention of
chiral integrity. This short 4-step sequence from simple
chiral commercial starting materials has enabled the explora-
tion of SAR. Arimoclomol (2) was then evaluated in general
pharmacology assays to assess selectivity over a representative
set of drug targets and pharmacokinetic data was generated
in vivo in mouse; these studies will be helpful towards a better
understanding of the PK-PD relationship of 2 in disease
models.
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